"14th Five-Year Plan" Hard-Core Achievements | First Domestic Version Officially Launched! Overcoming More Than Ten Technical Bottlenecks

With the aging population, the number of patients with aortic stenosis continues to rise, yet the penetration rate of suitable interventional treatments remains low. Clinical needs are urgent to be met. Targeting transcatheter aortic valve replacement, a challenging area in cardiac interventional therapy, New Pulse Medical has spent eight years overcoming more than a dozen technical bottlenecks and successfully completed the independent research and development of the Prizvalve valve system.

The Prizvalve valve system, led by the cardiology team at West China Hospital of Sichuan University and involving senior cardiology or cardiovascular surgery teams from a total of nine large tertiary hospitals in China, has undergone rigorous, professional, and scientific research and clinical validation, demonstrating that the system has achieved all safety and efficacy endpoints.

As a domestically innovative product benchmarking the latest generation of international technology, Prizvalve utilizes a ball-expandable short stent valve design to achieve innovative breakthroughs in multiple dimensions such as the valve frame, valve skirt, and delivery system, with over 80 patents applied for.

The launch of the Prizvalve valve system fills the technical gap in the domestic market for balloon valvuloplasty, providing a more comprehensive treatment option for millions of patients with aortic valve disease and marking the beginning of the era of balloon valvuloplasty in the interventional treatment of valvular diseases.